Interim Safety of RSVpreF Vaccination During Pregnancy

20260 citationsJournal Articlegreen Open Access

Authors

Ashley I. Michnick · Harvard University

Sarah C. MacDonald · Pfizer (United States)

Austin Cosgrove · Harvard Pilgrim Health Care

Sruthi Adimadhyam · Harvard University

Fang Zhang · Harvard University

Andrew B. Petrone · Harvard Pilgrim Health Care

Katherine E. Round ·

Abstract

This interim analysis of an ongoing retrospective cohort study uses data from 5 US health plans to assess safety of a bivalent prefusion F subunit–based respiratory syncytial virus (RSV) vaccine administered during pregnancy during the first full RSV season after US Food and Drug Administration approval (from September 22, 2023, through June 14, 2024).

Topics & Keywords

Respiratory viral infections research COVID-19 Impact on Reproduction Parvovirus B19 Infection Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAMA

Volume 335, Issue 5, pp. 456-456

DOI: 10.1001/jama.2025.23452

Field-Weighted Citation Impact: 0.00